The responsiveness of the different versions of the Hamilton Depression Scale

World Psychiatry

Volumn 14, Issue 3, 2015, Pages 309-310

  Bech, Per ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESVENLAFAXINE; ESCITALOPRAM; FLUOXETINE; PLACEBO; SERTRALINE;

ANXIETY; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; GUILT; HAMILTON DEPRESSION RATING SCALE; HAMILTON DEPRESSION RATING SCALE 17; HAMILTON DEPRESSION RATING SCALE 21; HAMILTON DEPRESSION RATING SCALE 28; HAMILTON DEPRESSION RATING SCALE 6; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NOTE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REMISSION; TREATMENT RESPONSE; VALIDITY;

EID: 84942521144     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20248     Document Type: Note

References (9)

1. Khan A, Brown WA,. Antidepressants versus placebo in major depression: an overview. World Psychiatry 2015; 14: 294-300.
2. Khan A, Bhat A, Kolts R, et al., Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 2010; 16: 217-26.
3. Bech P., Is the antidepressive effect of second-generation antidepressants a myth? Psychol Med 2010; 40: 181-6.
4. Fabre LF, Abuzzahab FS, Amin M, et al., Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995; 38: 592-602.
5. Liebowitz MR, Manley AL, Padmanabhan SK, et al., Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008; 24: 1877-90.
6. Bech P, Boyer P, Germain JM, et al., HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. Pharmacopsychiatry 2010; 43: 271-6.
7. Rush AJ, Kraemer HC, Sackeim HA, et al., Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31: 1841-53.
8. Ostergaard SD, Bech P, Trivedi MH, et al., Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the Research Domain Criteria (RDoC). J Affect Disord 2014; 163: 18-24.
9. Ostergaard SD, Bech P, Miskowiak KW., Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D6) as outcome measure. J Affect Disord (in press).